Drugs / Biocon Insulin R
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04022317 | Jun → Sep 2019 | — | Biocon Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biocon Insulin R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04022317 ↗ |
| Modality | Protein / enzyme biologic | “Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).” NCT04022317 ↗ |
| Route | Subcutaneous | “0.3 IU/kg Dose per administration, subcutaneous Route of administration” NCT04022317 ↗ |